AC Immune (ACIU) Projected to Post Quarterly Earnings on Tuesday

AC Immune (NASDAQ:ACIU) is expected to be posting its Q3 2025 results before the market opens on Tuesday, November 4th. Analysts expect AC Immune to post earnings of ($0.23) per share and revenue of $0.8060 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Friday, November 7, 2025 at 11:30 AM ET.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.05). AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%.The firm had revenue of $1.65 million for the quarter, compared to analysts’ expectations of $1.98 million. On average, analysts expect AC Immune to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AC Immune Price Performance

ACIU stock opened at $3.38 on Friday. AC Immune has a twelve month low of $1.43 and a twelve month high of $4.00. The stock has a market capitalization of $339.39 million, a price-to-earnings ratio of -5.83 and a beta of 1.56. The firm’s fifty day simple moving average is $2.81 and its two-hundred day simple moving average is $2.23.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ACIU shares. Zacks Research raised shares of AC Immune from a “strong sell” rating to a “hold” rating in a research report on Tuesday, September 9th. BTIG Research reaffirmed a “buy” rating and set a $8.00 target price on shares of AC Immune in a research note on Monday, September 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, AC Immune has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Trading of AC Immune

An institutional investor recently raised its position in AC Immune stock. Acadian Asset Management LLC boosted its position in shares of AC Immune (NASDAQ:ACIU) by 87.1% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 371,177 shares of the company’s stock after purchasing an additional 172,796 shares during the quarter. Acadian Asset Management LLC owned about 0.37% of AC Immune worth $679,000 as of its most recent filing with the Securities & Exchange Commission. 51.36% of the stock is currently owned by institutional investors and hedge funds.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.